Predictive Oncology has launched its innovative 3D cell culture model, which is aimed to enhance cancer drug discovery, as well as facilitate future drug development. Price details were not disclosed.

The 3D cell culture model designed by Predictive Oncology simulates human tissue more accurately than conventional 2D assays. Some of the key features include its organ- and disease-specific design, the ability to replicate the physiological environment of human tissue, and its compatibility with multiple cell types and drug classes. According to Predictive Oncology, this unique model allows for more precise predictions of clinical outcomes and aids in optimizing candidate selection for later clinical development. This could shorten the time it takes for drugs to reach the market, decrease costs, and reduce the necessity for animal testing.

Predictive Oncology is a biopharmaceutical company specializing in oncology drug discovery through the application of AI and ML. The company leverages its proprietary biobank, which contains over 150,000 tumor samples, to advance the development of cancer therapies.